Search / Trial NCT06617052

Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer

Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Sep 25, 2024

Trial Information

Current as of October 09, 2024

Not yet recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Age between 18 and 75 years
  • * ECOG performance status of 0-1
  • * Histologically, cytologically, or MRI/contrast-enhanced CT confirmed pelvic recurrence. At least one measurable pelvic lesion according to RECIST 1.1
  • * No distant metastases outside the pelvis
  • * (Potentially) resectable lesion
  • * No history of radiotherapy within the 6 months prior to enrollment
  • * No prior chemotherapy; or received postoperative adjuvant therapy but not systemic chemotherapy for metastatic lesions
  • * Investigator-assessed life expectancy of at least 24 weeks
  • * Adequate organ function (bone marrow, liver, kidney, and coagulation function) demonstrated within 7 days prior to the first dose, without the use of blood products or hematopoietic growth factors
  • * Not pregnant or breastfeeding. Effective contraception must be used during the study and for 6 months after the last dose
  • * Fully informed and willing to provide written informed consent to participate in the trial
  • Exclusion Criteria:
  • * Severe electrolyte abnormalities
  • * Active coronary artery disease, severe/unstable angina, newly diagnosed angina, or myocardial infarction within 12 months prior to study participation Thromboembolic events such as cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism, or deep vein thrombosis within the past 6 months
  • * New York Heart Association (NYHA) class II or higher congestive heart failure
  • * Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); untreated active hepatitis (hepatitis B defined as HBV-DNA ≥ 500 IU/ml, or hepatitis C defined as HCV-RNA above the detection limit of the assay) or co-infection with hepatitis B and C
  • * Active inflammatory bowel disease or other colorectal diseases causing chronic diarrhea
  • * Any active, known, or suspected autoimmune disease. Stable conditions not required systemic immunosuppressive therapy are allowed, such as type I diabetes, hypothyroidism requiring only hormone replacement therapy, and skin conditions (e.g., vitiligo, psoriasis, and alopecia) not requiring systemic treatment
  • * Interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, or acute pneumonia)
  • * Known or suspected history of allergy to any study-related medications
  • * Clinically detectable second primary malignancy or history of another malignancy within the past 5 years
  • * Pregnant or breastfeeding women, or women with a positive pregnancy test before the first dose, or female participants and their partners unwilling to use strict contraception during the study
  • * Any clinical or laboratory abnormalities or compliance issues that the investigator deems unsuitable for study participation
  • * Severe psychiatric disorders

About Sixth Affiliated Hospital, Sun Yat Sen University

The Sixth Affiliated Hospital of Sun Yat-sen University is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent academic hospital, it integrates clinical practice with research excellence, fostering collaboration among multidisciplinary teams to enhance medical knowledge and improve patient outcomes. The hospital is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, aiming to contribute to the global scientific community and support the development of new therapies and interventions. With a focus on translational medicine, the Sixth Affiliated Hospital actively engages in pioneering studies that address critical health challenges and promote evidence-based practices in diverse medical fields.

Locations

Guangzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0